ACAD Remlifanserin Fast Track: RADIANT Phase 2 Near-Miss

ACADIA Pharmaceuticals (ACAD) received FDA Fast Track designation for remlifanserin, an investigational 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The designation, announced July 20, 2026, came with Phase 2 topline data from the RADIANT trial, which read out September 25 as a near-miss.

ACAD closed at $24.84 on July 24. The stock has a market capitalization under $2 billion, making it a small-cap biotech where a single Phase 2 readout can move the stock materially.

Update September 26, 2026: The RADIANT Phase 2 topline read out September 25 — remlifanserin narrowly missed its primary endpoint (by four one-thousandths of a point), but Acadia is proceeding to a registrational Phase 3 program. ACAD fell to $20.68 (Polygon, September 25 close). See our Phase 2 analysis for the full read.

Price update August 6, 2026 (Polygon): ACAD closed at $28.80 on August 5 (Polygon), up 15.9% from the $24.84 reference price in this article. The stock has steadily climbed over the past two weeks, driven by broader sector strength and positioning ahead of the RADIANT Phase 2 topline data expected in September-October. Market cap is now approximately $2.2B. The investment thesis and risks below remain unchanged — the Phase 2 readout is the binary catalyst.

A market with zero approved therapies

Alzheimer’s disease psychosis affects up to 50% of AD patients and is associated with faster cognitive decline, increased caregiver burden, and earlier nursing home placement. There are no FDA-approved treatments specifically for ADP. Current management relies on off-label antipsychotics such as quetiapine and risperidone, which carry black-box warnings for increased mortality in elderly dementia patients. The FDA has repeatedly refused to approve antipsychotics for dementia-related psychosis due to safety concerns.

That regulatory history is why Fast Track designation matters. The program expedites development and review for serious conditions with unmet medical need. It provides more frequent FDA interaction, potential priority review vouchers, and a faster pathway if the data support approval. ACADIA already holds the only FDA-approved treatment for Parkinson’s disease psychosis, Nuplazid (pimavanserin), approved in 2016 with the same 5-HT2A mechanism. Nuplazid generated $628 million in 2025 revenue.

How remlifanserin differs

Remlifanserin (ACP-204) is a potent, highly selective 5-HT2A receptor inverse agonist designed to reduce hallucinations and delusions by restoring excitatory/inhibitory balance without direct dopamine D2 blockade. That avoids the safety issues associated with atypical antipsychotics, including extrapyramidal symptoms, sedation, and the increased mortality risk that triggered black-box warnings.

Nuplazid also targets 5-HT2A but for Parkinson’s psychosis. The Alzheimer’s psychosis market is substantially larger: roughly 6.9 million Americans live with Alzheimer’s, and up to 50% develop psychosis. A successful remlifanserin approval would more than double ACADIA’s addressable patient population.

The RADIANT program

RADIANT uses an adaptive trial design allowing Phase 3 enrollment to proceed alongside the completed Phase 2 portion. ACADIA completed Phase 2 enrollment and reported topline results September 25, 2026 — a near-miss on the primary endpoint. The trial evaluates remlifanserin for both Alzheimer’s disease psychosis and Lewy body dementia-associated psychosis.

The adaptive design meant a positive Phase 2 readout this fall could accelerate the path to an NDA filing. The Phase 2 primary endpoint narrowly missed, but Acadia is proceeding to a registrational Phase 3 program on the secondary signals. The catalyst has now resolved.

Risks

The 5-HT2A inverse agonism mechanism is not new. Nuplazid’s 2016 approval was controversial due to modest efficacy (only 2 of 3 Phase 3 trials were positive) and post-marketing safety reports including deaths. The FDA required a boxed warning. If remlifanserin faces similar scrutiny, Fast Track will not save the program.

Competition in dementia-related psychosis is limited but growing. Otsuka and H. Lundbeck’s Rexulti (brexpiprazole) holds an FDA approval for agitation in Alzheimer’s dementia, a related but distinct indication.

ACADIA’s $628 million Nuplazid franchise faces patent cliff pressure, with composition-of-matter patents expiring in the late 2020s. Remlifanserin is the pipeline asset the company needs to sustain growth.

For a broader look at Alzheimer’s drug development, see our Biogen diranersen tau-targeting analysis — another Phase 2 Alzheimer’s program with Phase 3 risk.

What to watch next

The RADIANT Phase 2 topline read out September 25 as a near-miss, and Acadia is proceeding to a registrational Phase 3 program. Watch whether the Phase 3 confirms the secondary-signal effect, which would position remlifanserin for accelerated development.

ACADIA press release | Yahoo Finance coverage